Medical News

RSS

New Cleveland Clinic study shows bariatric surgery is safe option for managing type 2 diabetes in overweight or mildly obese patients

Weight-loss surgery, long considered a treatment largely reserved for people with severe obesity, may also be a good and safe option for the treatment of uncontrolled type 2 diabetes in those who are overweight or have mild to moderate obesity, according to researchers from Cleveland Clinic in Ohio.

10 Nov 2015

Gastric balloon in a pill helps patients lose weight without surgery or endoscopy

A new gastric balloon that can be swallowed like a pill and then filled while in the stomach, helped patients lose more than 37 percent of their excess weight over four months, according to new research presented here at ObesityWeek 2015, the largest international event focused on the basic science, clinical application and prevention and treatment of obesity. The weeklong conference is hosted by the American Society for Metabolic and Bariatric Surgery (ASMBS) and The Obesity Society (TOS).

10 Nov 2015

Astellas enters into definitive agreement to acquire Ocata

Astellas Pharma Inc. and Ocata Therapeutics, Inc., a biotechnology company focused on the research and development of new therapies in the field of regenerative medicine, primarily cell therapy addressing unmet medical needs in ophthalmology patients, announced today that they have entered into a definitive agreement.

10 Nov 2015

Obesity groups take aim at states that deny coverage of obesity treatment under affordable care act

The American Society for Metabolic and Bariatric Surgery (ASMBS) and groups including The Obesity Society (TOS) and Academy for Nutrition and Dietetics (AND), filed a complaint this month with U.S. Health and Human Services (HHS) claiming the 27 states that deny coverage for bariatric surgery are in non-compliance with the Affordable Care Act (ACA) and that their failure to comply is discriminatory against women and people with disabilities, and violates the ban against denying coverage based on health status or a pre-existing condition.

10 Nov 2015

New funding for Centenary's life saving research

The Centenary Institute has welcomed the Federal Government’s announcement of funding for 9 new and innovative medical research projects via the latest round of NHMRC grant rounds funding, officially confirmed today.

9 Nov 2015

Cancer survivors' journeys chronicled by Bethlehem artist and cancer survivor Susan Schaffer

Chronicling the journeys of cancer survivors, friends and family has been an emotional process, one filled with joy and shared sorrow for Bethlehem artist and cancer survivor Susan H. Schaffer. As part of her Visions of Hope series of acrylic paintings, Susan offers insight into the windows of the soul - her collection captures the eyes of the people willing to share their respective cancer journeys with her.

9 Nov 2015

Paratek initiates Omadacycline phase 3 clinical study in community acquired bacterial pneumonia (CABP)

Paratek Pharmaceuticals, Inc. has announced the dosing of the first patient in its Phase 3 clinical study of its lead drug candidate, omadacycline, for the treatment of Community Acquired Bacterial Pneumonia (CABP). This global Phase 3 study will assess the efficacy and safety of omadacycline compared with moxifloxacin in subjects with CABP.

9 Nov 2015

AACR rapid and dramatic responses in TRK fusion patients

Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

9 Nov 2015

Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.

9 Nov 2015

St. Jude and Scripps Research Institute scientists help launch Human Dark Proteome Initiative

Scientists at St. Jude Children’s Research Hospital, The Scripps Research Institute (TSRI) and other institutions today announced the launch of the Human Dark Proteome Initiative (HDPI). The initiative aims to accelerate research into biology’s “invisible mass” to provide novel insights into cell function and a new frontier in drug discovery.

9 Nov 2015

Glan Clwyd Hospital N Wales invest in Esaote's G-Scan MRI unit for weight-bearing scanning

Glan Clwyd Hospital in North Wales has become the first publicly-funded hospital in the UK to invest in Esaote’s G-scan Brio, an open, weight-bearing MRI unit for musculoskeletal scanning. In an innovative move, the hospital can now scan patients in any position, from standing vertically to the traditional supine postition laying flat.

9 Nov 2015

Oasmia Pharmaceutical’s Paclical is bioequivalent of Celgene’s Abraxane in treatment of women with metastatic breast cancer

Oasmia Pharmaceutical AB, a developer of a new generation of drugs within human and veterinary oncology, confirmed today the previously published findings from a head-to-head comparison study of its lead human cancer product Paclical and Celgene’s Abraxane, demonstrated superimposable paclitaxel PK profiles. The study was conducted in women with metastatic breast cancer.

9 Nov 2015

Armaron Bio starts Phase 2 trial for novel lead candidate drug for heart failure

Armaron Bio, a Melbourne-based drug development company focused on heart failure and other diseases, is pleased to announce that it has begun its Phase II clinical trial for NP202, its novel lead candidate drug for heart failure.

9 Nov 2015

First comprehensive genomic and biologic study of top skin disease-causing microbes

An international team of scientists, led by researchers from A*STAR's Genome Institute of Singapore (GIS), Institute of Medical Biology (IMB), and Bioinformatics Institute (BII), and P&G, have completed the first comprehensive genomic and biologic study of all species of Malassezia, one of the top skin disease-causing microbes.

9 Nov 2015

WHO praises Sierra Leone for stopping Ebola transmission

The World Health Organization declares that Ebola virus transmission has been stopped in Sierra Leone. Forty-two days, that is two Ebola virus incubation cycles, have now passed since the last person confirmed to have Ebola virus disease had a second negative blood test.

9 Nov 2015

Medication not psychotherapy intensity sways treatment outcome in adult ADHD

Psychological interventions for adult attention deficit/hyperactivity disorder are best combined with methylphenidate, show findings from the COMPAS trial.

9 Nov 2015

Presence of tophi in people with gout can increase risk of developing cardiovascular disease

The presence of tophi - crystal deposits of uric acid found on the surface of the joints or in the skin and cartilage - in people with gout can increase their risk of developing cardiovascular disease, according to research presented this week at the American College of Rheumatology Annual Meeting in San Francisco.

9 Nov 2015

HIFU Prostate Services announces groundbreaking partnerships to offer prostate cancer treatments

HIFU Prostate Services, LLC, a leading provider of minimally-invasive prostate cancer treatment using High Intensity Focused Ultrasound ("HIFU"), announces groundbreaking partnerships with Michael J. Lazar, MD in Santa Rosa, Calif. and John H. Jurige, MD in Louisville, Ky., to offer HIFU treatments for prostate cancer.

9 Nov 2015

Nightstar announces $35 million Series B financing round

NightstaRx Ltd, a biopharmaceutical company specialising in developing gene therapies for inherited retinal dystrophies, announces a $35 million Series B financing round. The round was led by New Enterprise Associates, one of the world's leading venture capital firms.

9 Nov 2015

Arthritis patients to be greater contributors to clinical guideline development

CreakyJoints®, the online, non-profit, arthritis patient support community with more than 80,000 members, today announced the publication of “When patients write the guidelines: Patient panel recommendations for the treatment of rheumatoid arthritis,” in Arthritis Care & Research (AC&R), an official journal of the American College of Rheumatology (ACR).

9 Nov 2015

Medical News

New Cleveland Clinic study shows bariatric surgery is safe option for managing type 2 diabetes in overweight or mildly obese patients

Gastric balloon in a pill helps patients lose weight without surgery or endoscopy

Astellas enters into definitive agreement to acquire Ocata

Obesity groups take aim at states that deny coverage of obesity treatment under affordable care act

New funding for Centenary's life saving research

Cancer survivors' journeys chronicled by Bethlehem artist and cancer survivor Susan Schaffer

Paratek initiates Omadacycline phase 3 clinical study in community acquired bacterial pneumonia (CABP)

AACR rapid and dramatic responses in TRK fusion patients

Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

St. Jude and Scripps Research Institute scientists help launch Human Dark Proteome Initiative

Glan Clwyd Hospital N Wales invest in Esaote's G-Scan MRI unit for weight-bearing scanning

Oasmia Pharmaceutical’s Paclical is bioequivalent of Celgene’s Abraxane in treatment of women with metastatic breast cancer

Armaron Bio starts Phase 2 trial for novel lead candidate drug for heart failure

First comprehensive genomic and biologic study of top skin disease-causing microbes

WHO praises Sierra Leone for stopping Ebola transmission

Medication not psychotherapy intensity sways treatment outcome in adult ADHD

Presence of tophi in people with gout can increase risk of developing cardiovascular disease

HIFU Prostate Services announces groundbreaking partnerships to offer prostate cancer treatments

Nightstar announces $35 million Series B financing round

Arthritis patients to be greater contributors to clinical guideline development

How real-time off-gas analysis improves fermentation process control

Advancing Drug Safety Assessment With AI, Predictive Modeling, and Human-Relevant Data

AI-powered analytics and experimental validation

Latest News